Loss-of-function mutations in PPARγ associated with human colon cancer

Molecular Cell

Volumn 3, Issue 6, 1999, Pages 799-804

  Sarraf, Pasha ^a   Mueller, Elisabetta ^a   Smith, Wendy M ^b   Wright, Harold M ^a   Jennifer B, Kum ^b   Aaltonen, Lauri A ^c   De Chapelle, Albert la ^b   Spiegelman, Bruce M ^a   Charis, Eng ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; COLON CANCER; DNA POLYMORPHISM; FRAMESHIFT MUTATION; GENE LOSS; GENE MUTATION; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; IN SITU HYBRIDIZATION; LIGAND BINDING; MISSENSE MUTATION; NONSENSE MUTATION; PROTEIN BINDING; SOMATIC MUTATION;

EID: 0033152206     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(01)80012-5     Document Type: Article

References (28)

1. Adams, M., Reginato, M.J., Shao, D., Lazar, M.A., and Chatterjee, V.K. (1997). Transcriptional activation by peroxisome proliferator- Activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128-5132.
2. Brockman, J.A., Gupta, R.A., and Dubois, R.N. (1998). Activation of ppargamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115, 1049-1055.
3. Cook, D.L., Gerber, A.N., and Tapscott, S.J. (1998). Modeling stochastic gene expression: Implications for haploinsufficiency. Proc. Natl. Acad. Sci. USA 95, 15641-15646.
4. Demetri, G.D., Fletcher, C.D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B.M., and Singer, S. (1999). Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 96, 3951-3956.
5. Elstner, E., Muller, C., Koshizuka, K., Williamson, E.A., Park, D., Asou, H., Shintaku, P., Said, J.W., Heber, D., and Koeffler, H.P. (1998). Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA 95, 8806-8811
6. Eng, C. (1999). RET proto-oncogene in the development of human cancer. J. Clin. Oncol. 17, 380-393.
7. Eng, C., Schneider, K., Fraumeni, J.F., and Li, F.P. (1997). Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in li-fraumeni syndrome. Cancer Epidemiol. Biomarkers Prev. 6, 379-383.
8. Fearon, E.R., and Vogelstein, B. (1992). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
9. 2 is a ligand for the adipocyte determination factor pparτ. Cell 83, 803-812.
10. Greenblatt, M.S., Bennett, W.P., Hollstein, M., and Harris, C.C. (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
11. Hu, E., Kim, J.B., Sarraf, P., and Spiegelman, B.M. (1996). Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of ppargamma. Science 274, 2100-2103.
12. Kinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell 87, 159-170.
13. Kliewer, S.A., Lenhard, J.M., Willson, T.M., Patel, I., Morris, D.C., and Lehmann, J.M. (1995). A prostaglandin j2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813-819.
14. Kubota, T., Koshizuka, K., Williamson, E.A., Asou, H., Said, J.W., Holden, S., Miyoshi, I., and Koeffler, H.P. (1998). Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344-3352.
15. Levebvre, A.-M., Chen, I., Desreumaux, P., Najib, N., Fruchart, J.-C., Geboes, K., Briggs, M.,Heyman, R.,and Auwerx, J. (1998). Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in c57bl/6j-apcmin/+ mice. Nat. Med. 4, 1053-1056.
16. Liaw, D., Marsh, D.J., Li, J., Dahia, P.L. M., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., et al. (1997). Germline mutations of the PTEN gene in cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16, 64-67.
17. Marsh, D.J., Coulon, V., Lunetta, K.L., Rocca-Serra, P., Dahia, P.L.M., Zheng, Z., Liaw, D., Caron, S., Duboué, B., Lin, A.Y., et al. (1998a). Mutation spectrum and genotype-phenotype analyses in cowden disease and bannayan-zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. 7, 507-515.
18. Marsh, D.J., Dahia, P.L. M., Coulon, V., Zheng, Z., Dorion-Bonnet, F., Call, K.M., Little, R., Lin, A.Y., Eeles, R.A., Goldstein, A.M., et al. (1998b). Allelic imbalance, including deletion of PTEN/MMAC1, at the cowden disease locus on 10q22-23, in hamartomas from patients with cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer 21, 61-69.
19. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R.M., Martin, K.J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B.M. (1998). Terminal differentiation of human breast cancer through pparγ. Mol. Cell 1, 465-470.
20. Nagy, L., Tontonoz, P., Alvarez, J.G.A., Chen, H., and Evans, R.M. (1998). Oxidised LDL regulates macrophage gene expression through ligand activation of pparγ. Cell 93, 229-240.
21. Nolte, R.T., Wisely, G.B., Westin, S., Cobb, J.E., Lambert, M.H., Kurokawa, R., Rosenfeld, M.G., Willson, T.M., Glass, C.K., and MilBurn, M.V. (1998). Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor γ. Nature 395, 137-143.
22. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
23. Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W., and Kahn, C.R. (1998). Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339, 953-959.
24. Saez, E., Tontonoz, P., Nelson, M.C., Alvarez, J.G.A., Tze, M.U., Baird, S.M., Thomazy, V.A., and Evans, R.M. (1998). Activators of the nuclear receptor pparγ enhance colon polyp formation. Nat. Med. 4, 1058-1061.
25. Sarraf, P., Mueller, E., Jones, D., King, F.J., Deangelo, D.J., ParTridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher, C., and Spiegelman, B.M. (1998). Differentiation and reversal of malignant changes in colon cancer through pparγ. Nat. Med. 4, 1046-1052.
26. Spiegelman, B.M. (1998). Ppargamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514.
27. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. (1998). Pparγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
28. Webb, C.P., van Aelst, L., Wigler, M.H., and van der Woude, G.f. (1998). Signaling pathways in ras-mediated tumorigenecity and metastases. Proc. Natl. Acad. Sci. USA 95, 8773-8778.